Human BCMA/TNFRSF17 Fluorescein-conjugated Antibody Summary
Met1-Ala54
Accession # Q6PE46
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Scientific Data
Detection of BCMA/TNFRSF17 in RPMI 8226 Human Cell Line by Flow Cytometry. RPMI 8226 human multiple myeloma cell line was stained with Goat Anti-Human BCMA/TNFRSF17 Fluorescein-conjugated Antigen Affinity-purified Polyclonal Antibody (Catalog # FAB193F, filled histogram) or control antibody (Catalog # IC108F, open histogram). View our protocol for Staining Membrane-associated Proteins.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, 2 to 8 °C as supplied.
Background: BCMA/TNFRSF17
BCMA, B cell maturation, is a member of the TNF receptor superfamily. It has been designated TNFRSF17. BCMA is a type III membrane protein containing one extracellular cysteine rich domain. Within the TNFRSF, it shares the highest homology with TACI. BCMA and TACI have both been shown to bind to APRIL and BAFF, members of the TNF ligand superfamily. BCMA expression has been found in immune organs and mature B cell lines. Although some expression has been observed at the cell surface, BCMA appears to be localized to the Golgi compartment. The binding of BCMA to APRIL or BAFF has been shown to stimulate IgM production in peripheral blood B cells and increase the survival of cultured B cells. This data suggests that BCMA may play an important role in B cell development, function and regulation. Human BCMA is a 184 amino acid (aa) protein consisting of a 54 aa extracellular domain, a 23 aa transmembrane domain, and a 107 aa intracellular domain. Mouse and human BCMA share 62% amino acid identity.
- Madry, C. et al. (1998) Int. Immunol. 10:1693.
- Gras, M. et al. (1995) Int. Immunol. 7:1093.
- Kwon, B. et al. (1999) Curr. Opin. Immunol. 11:340.
- Marsters, S. et al. (2000) Curr. Biol. 10:785.
- Thompson, J. et al. (2000) J. Exp. Med. 192:129.
Product Datasheets
Citation for Human BCMA/TNFRSF17 Fluorescein-conjugated Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
1 Citation: Showing 1 - 1
-
BAFF is increased in renal transplant patients following treatment with alemtuzumab.
Authors: Bloom D, Chang Z, Pauly K
Am. J. Transplant., 2009-06-12;9(8):1835-45.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human BCMA/TNFRSF17 Fluorescein-conjugated Antibody
There are currently no reviews for this product. Be the first to review Human BCMA/TNFRSF17 Fluorescein-conjugated Antibody and earn rewards!
Have you used Human BCMA/TNFRSF17 Fluorescein-conjugated Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image